National LCS rates were unchanged between 2019 and 2020; significant declines seen in five states and increases recorded in 19 states
Seven graded recommendations and nine ungraded consensus statements developed for lung cancer screening
Risks for all-cause mortality, cancer-specific mortality, disease progression reduced for those quitting after diagnosis
No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease
Objective response seen in 37.1 percent of patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer
Any degree of aortic valve calcification was identified in 13.1 percent of participants; 0.5 percent had at least moderate AS
Lumakras is approved for use in adults with KRAS G12C-mutated non-small cell lung cancer
Risk for recurrence increased with surgical delay beyond 12 weeks; overall survival improved with surgery within 12 weeks
Efficacy data revealed 40 percent response rate, median response duration of 11.1 months
Deep learning algorithm could aid malignancy risk estimation of pulmonary nodules detected on low-dose screening CT